1. 1193PDAnalysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials. (1st October 2019) Authors: Reck, M; Feng, Y; Kim, H R; Plautz, G; Kang, Y-K; Owonikoko, T K; Nghiem, P; Sheng, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 149OEfficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. (25th November 2018) Authors: Kang, Y-K; Kudo, M; Lim, H-Y; Hsu, C-H; Vogel, A; Brandi, G; Cheng, R; Carton, I; Abada, P; Hsu, Y; Zhu, A; Yen, C-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1620PPhase II study of paclitaxel in patients with advanced gastrointestinal stromal tumor (GIST) after failure of at least both imatinib and sunitinib. (23rd October 2018) Authors: Cho, H; Ryu, M-H; Kim, B J; Park, Y; Na, Y-S; Ma, J; Beck, M Y; Kang, Y-K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 1623PCorrelation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib. (23rd October 2018) Authors: George, S; Bauer, S; Jones, R L; Serrano, C; von Mehren, M; Kang, Y-K; Schöffski, P; Cassier, P; Eskens, F A; Mir, O; Tap, W D; Chawla, S P; Rutkowski, P; Shi, H; Schmidt-Kittler, O; Mar, B; Heinrich, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 1662TiPVOYAGER: An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST). (23rd October 2018) Authors: Bauer, S; George, S; Kang, Y-K; Tap, W D; Zhou, T; Picazio, N; Boral, A L; Heinrich, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 617PDA phase III study of nivolumab (nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data. (23rd October 2018) Authors: Satoh, T; Chen, L-T; Kang, Y-K; Chao, Y; Kato, K; Chung, H C; Chen, J-S; Muro, K; Kang, W K; Yoshikawa, T; Oh, S C; Tamura, T; Lee, K-W; Boku, N Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 61OSafety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours. (24th November 2019) Authors: Oh, D-Y; Hamilton, E; Hanna, D; Beeram, M; Lee, K-W; Kang, Y-K; Chaves, J; Lee, J-Y; Goodwin, R; Vaklavas, C; Rha, S-Y; Elimova, E; Mayordomo, J; Ferrario, C; Cobleigh, M; Fortenberry, A; Rowse, G; Gray, T; Lai, R; Bernstam, F Meric Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 661PUpdated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. (23rd October 2018) Authors: Bang, Y-J; Doi, T; Kondo, S; Chung, H C; Muro, K; Dussault, I; Helwig, C; Osada, M; Kang, Y-K Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 662PBiomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA). (23rd October 2018) Authors: Catenacci, D V T; Park, H; Uronis, H E; Kang, Y-K; Ng, M; Gold, P; Lacy, J; Enzinger, P C; Park, S; Lee, K-W; Yen, J; Odegaard, J; Franovic, A; Baughman, J; Muth, J; Wynter-Horton, A; Wu, T; Wigginton, J; Davidson-Moncada, J K; Bang, Y-J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. (17th December 2018) Authors: Deva, S; Lee, J-S; Lin, C-C; Yen, C-J; Millward, M; Chao, Y; Keam, B; Jameson, M; Hou, M-M; Kang, Y-K; Markman, B; Lu, C-H; Rau, K-M; Lee, K-H; Horvath, L; Friedlander, M; Hill, A; Wu, J; Hou, J; Desai, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 10 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗